ConductScience.org, home

Paper799563

Evaluation of the effect of timolol alone and in combination with hydrochlorothiazide and amiloride in the treatment of mild to moderate arterial hypertension: a double-blind, controlled study.

Muiesan G and 5 others. Clin Sci Mol Med Suppl, 1976. Cited by 6 papers, by iCite.

Cite this record

ConductScience Library. Evaluation of the effect of timolol alone and in combination with hydrochlorothiazide and amiloride in the treatment of mild to moderate arterial hypertension: a double-blind, controlled study. Papers, record 799563. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/799563

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Evaluation of the effect of timolol alone and in combination with hydrochlorothiazide and amiloride in the treatment of mild to moderate arterial hypertension: a double-blind, controlled study.
PubMed
Journal
Clin Sci Mol Med Suppl
PubMed
Year
1976
PubMed
Publication types
Clinical Trial, Journal Article, Randomized Controlled Trial
PubMed
Citations, by iCite
6
iCite
Relative citation ratio, by iCite
0.31
iCite
Revised in PubMed
2019-10-28
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Muiesan GG
2Magnani BB
3Agabiti-Rosei EE
4Alicandri CC
5Ambrosioni EE
6Miele NN

Source PubMed

Download CSV of authors

Topics14

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
AmilorideMajor topic
HydrochlorothiazideMajor topic
HypertensionMajor topic
PropanolaminesMajor topic
PyrazinesMajor topic
TimololMajor topic
Adult
Clinical Trials as Topic
Drug Therapy, Combination
Female
Heart Rate
Humans
Male
Middle Aged

Source PubMed

Download CSV of topics

Cited by5

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 6 citations.

PMIDTitleJournalYearIn PapersSource
20091622Blood pressure lowering efficacy of beta-blockers as second-line therapy for primary hypertension.Cochrane Database Syst Rev2010https://conductscience.org/library/papers/20091622PubMed
19821398Blood pressure lowering efficacy of diuretics as second-line therapy for primary hypertension.Cochrane Database Syst Rev2009https://conductscience.org/library/papers/19821398PubMed
12826783Achieving goal blood pressure in patients with type 2 diabetes: conventional versus fixed-dose combination approaches.J Clin Hypertens (Greenwich)2003https://conductscience.org/library/papers/12826783PubMed
7049710Clinical evaluation of labetalol alone and combined with chlorthalidone in essential hypertension: a double-blind multicentre controlled study.Eur J Clin Pharmacol1982https://conductscience.org/library/papers/7049710PubMed
365544Timolol and bendrofluazide in the management of hypertension in general practice.Eur J Clin Pharmacol1978https://conductscience.org/library/papers/365544PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/799563

GET https://conductscience.org/api/papers/v1/799563/authors